CAS: 1895-39-2; Sodium 2-Chloro-2,2-Difluoroacetate

相似化合物

2923-18-4 76-04-0 1514-87-0

上下游产品

CAS号1111637-77-4 3-(二氟甲氧基)-2-硝基吡啶 | CAS号383-62-0 二氟氯乙酸乙酯 | CAS号52026-98-9 4-氯-2,3,5,6-四氟吡啶 | CAS号1979-51-7 2-苯基五氟丙烯 | CAS号1979-54-0 1-fluoro-4-(1,1... | CAS号2488-66-6 对二氟甲硫基氯苯 | CAS号85684-61-3 3-(二氟甲氧基)苯甲醛 | CAS号888327-32-0 5-溴-2-(二氟甲氧基)甲苯 | CAS号954235-83-7 1-溴-2-(二氟甲氧基)-4-氟苯 | CAS号75-45-6 一氯二氟甲烷

专利信息

专利号:EP-0799313-A2
优先权日:1994-12-13
标 题 :Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
发明人：BEIGELMAN LEONID; STINCHCOMB DANIEL T; JARVIS THALE; DRAPER KENNETH; PAVCO PAMELA; MCSWIGGEN JAMES; GUSTOFSON JOHN; USMAN NASSIM; WINCOTT FRANCINE; MATULIC-ADAMIC JASENKA; KARPEISKY ALEXANDER; THOMPSON JAMES D; MODAK ANIL; BURGIN ALEX
权利人:RIBOZYME PHARM INC
摘要:An enzymatic nucleic acid molecule which cleaves RNA associated with development or maintenance of an arthritic condition, induction of graft tolerance or reversal of an immune response. In particular, the ribozyme sequences are directed to an mRNA encoding B7-1, B7-2, B7-3, CD40 and/or stromelysin. Also provided are ribozymes where the uracil in positions 4 and/or 7 are substituted, as well as methods for the synthesis of 2'-alkylnucleotides, 2'-O-alkylthioalkyl, or 2'-alkylthioalkylnucleotides. The application further describes a method for diprotection of RNA with aqueous ethylamine, a method for synthesis of a basic ribonucleoside mimetics, and transcription units comprising an RNA polymerase II promoter, a U6 small nuclear promoter, or an adenovirus VA1 promoter system.

专利号:WO-2025128873-A1
优先权日:2023-12-12
标题:Heterocyclic pyridinone compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

专利号:US-2009264648-A1
优先权日:2008-01-14
标题:Synthesis of pyrazoles
发明人：CHEW WARREN; WANG ZHENG; CHEAL GLORIA; BERTRAND MARTIAL; POTOSKI JOHN; MIRMEHRABI MAHMOUD; NENCINI ARIANNA; ZANALETTI RICCARDO
权利人:WYETH CORP; SIENA BIOTECH SPA
摘要:The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

专利号:US-9242998-B2
优先权日:2013-02-07
标题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
发明人：HE SHUWEN; DAI XING; PALANI ANANDAN; NARGUND RAVI; LAI ZHONG; ZORN NICOLAS; XIAO DONG; DANG QUN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD
权利人:HE SHUWEN; DAI XING; PALANI ANANDAN; NARGUND RAVI; LAI ZHONG; ZORN NICOLAS; XIAO DONG; DANG QUN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-6245919-B1
优先权日:1996-06-28
标 题:Cyclopropylglycine derivatives and agonists for metabotronic L-glutamate receptors
发明人：SHINOZAKI HARUHIKO; TAGUCHI TAKEO; ISHIDA MICHIKO
权利人:SHINOZAKI HARUHIKO; TAGUSHI TAKEO; NIPPON CHEMIPHAR CO
摘要:A cyclopropylglycine derivative having the following formula:and an intermediate compound for the synthesis of the cyclopropylglycine derivative are novel compounds. The cyclopropylglycine derivative shows a selectivity higher than that of the known agonists to metabotropic L-glutamate receptors, and therefore is a metabotropic type agonist to L-glutamate which has excellent characteristics.

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).